WCN25-2412 COMBINED INDUCTION THERAPY WITH RABBIT ANTI-THYMOCYTE GLOBULIN (rATG) AND RITUXIMAB IN COMPARISON WITH rATG ALONE ON RENAL ALLOGRAFT OUTCOMES IN NON-SENSITIZED LIVE RECIPIENTS
Antibody-mediated rejections are the most common cause of graft loss. Induction therapy with ATG is T cell centric leaving B cells uninhibited leading to acute rejections and antibody-mediated IF/TA in the long term. Combined T cell and B cell inhibition might prevent Acute rejections, ABMR and improve graft survival.
Authors
- V. Siddini
- Rohan Augustine
- G Praveen (ORCID: https://orcid.org/0000-0003-2361-7575)
- Sudarshan Ballal
Institutions
- Manipal Hospital (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.915
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00